RCKT ROCKET PHARMACEUTICALS, INC.
Price Chart
Executive Summary
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in gross proceeds, a previously announced transaction. The non-dilutive capital infusion boosts pro-forma cash to approximately $322.6 million and extends the company's cash runway into the second quarter of 2028, strengthening its balance sheet as it advances its cardiovascular gene therapy pipeline.
Actionable Insight
The closing removes completion risk and solidifies the balance sheet. With extended runway into Q2 2028, the company has increased financial flexibility to execute on its cardiovascular gene therapy pipeline. Monitor for upcoming clinical catalysts and potential business development activities enabled by this liquidity.
Key Facts
- Completed sale of PRV for $180.0 million in gross proceeds
- Pro-forma cash, cash equivalents and investments increased to approximately $322.6 million
- Cash runway extended into Q2 2028
- Transaction closed on June 10, 2026, announced via press release on June 12, 2026
- PRV was originally granted by the FDA in March 2026 in connection with KRESLADI approval
Financial Impact
Gross proceeds of $180.0 million added; pre-sale cash was $144.4 million, post-sale pro forma cash ~$322.6 million
Risk Factors
- Pipeline execution and clinical trial risks remain
- Stock may have already priced in the PRV sale from the prior announcement
- One-time monetization event without recurring revenue impact
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-024997 |
| Document: ef20076119_ex99-1.htm | 0001140361-26-024997 |
| Document: 0001140361-26-024997-index-headers.html | 0001140361-26-024997 |
| Document: 0001140361-26-024997-index.html | 0001140361-26-024997 |
| Document: 0001140361-26-024997.txt | 0001140361-26-024997 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
3d ago
|
8-K
| $2.77 awaiting T+5 | awaiting T+5 | — | $2.75 (−0.72%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $2.99 $2.92 | ▼ −2.34% | ▼ −2.81% | $2.75 (−8.03%) |
|
May 7, 2026
5w ago
|
Insider Cluster
| $3.25 $2.96 | ▼ −8.92% | ▼ −9.89% | $2.75 (−15.38%) |
|
Mar 11, 2026
13w ago
|
EFFECT
| $4.96 $4.47 | ▼ −9.88% | ▼ −7.69% | $2.75 (−44.56%) |
|
Mar 2, 2026
14w ago
|
S-3
| $4.80 $5.30 | ▼ −10.42% | ▼ −10.89% | $2.75 (+42.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access